Yongkun Sun

2.4k total citations · 1 hit paper
86 papers, 1.6k citations indexed

About

Yongkun Sun is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yongkun Sun has authored 86 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 28 papers in Surgery. Recurrent topics in Yongkun Sun's work include Gastric Cancer Management and Outcomes (23 papers), Colorectal Cancer Treatments and Studies (17 papers) and Lung Cancer Research Studies (12 papers). Yongkun Sun is often cited by papers focused on Gastric Cancer Management and Outcomes (23 papers), Colorectal Cancer Treatments and Studies (17 papers) and Lung Cancer Research Studies (12 papers). Yongkun Sun collaborates with scholars based in China, United States and Australia. Yongkun Sun's co-authors include Yihebali Chi, Jinwan Wang, Feng Du, Hao Yu, Chunxia Du, Wei Niu, Li Li, Shuting Li, Chuan Li and Feng‐Qing Wang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

Yongkun Sun

79 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

2016 332 citations Yongkun Sun, Feng Du et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yongkun Sun China	18	857	671	359	332	212	86	1.6k
Zhehai Wang China	22	1.0k 1.2×	844 1.3×	230 0.6×	445 1.3×	120 0.6×	81	1.7k
Liliana Montella Italy	23	594 0.7×	436 0.6×	286 0.8×	262 0.8×	239 1.1×	102	1.6k
K. Syrigos Greece	23	1.1k 1.3×	638 1.0×	246 0.7×	388 1.2×	165 0.8×	73	1.9k
Soichiro Funaki Japan	22	616 0.7×	683 1.0×	335 0.9×	346 1.0×	204 1.0×	146	1.7k
István Molnár United States	18	566 0.7×	277 0.4×	249 0.7×	464 1.4×	162 0.8×	45	2.1k
Shigeo Hisamori Japan	23	689 0.8×	719 1.1×	628 1.7×	401 1.2×	72 0.3×	69	1.9k
Isamu Makino Japan	23	711 0.8×	470 0.7×	585 1.6×	363 1.1×	182 0.9×	136	1.6k
Paolo Castellano Italy	21	1.0k 1.2×	642 1.0×	485 1.4×	383 1.2×	56 0.3×	32	1.7k

Countries citing papers authored by Yongkun Sun

Since Specialization

Citations

This map shows the geographic impact of Yongkun Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongkun Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongkun Sun more than expected).

Fields of papers citing papers by Yongkun Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongkun Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongkun Sun. The network helps show where Yongkun Sun may publish in the future.

Co-authorship network of co-authors of Yongkun Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Yongkun Sun. A scholar is included among the top collaborators of Yongkun Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongkun Sun. Yongkun Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Yongkun, et al.. (2025). Astragaloside IV Improves Cyclophosphamide-Induced Liver Injury in Mice by Mediating Immunosuppression and Oxidative Stress Through the PI3K/Akt Signaling Pathway: A Randomized Trial. Hepatitis Monthly. 25(1).

Fang, Yuting, et al.. (2025). Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma. BMC Gastroenterology. 25(1). 266–266.

Xie, Yibin, Wen Zhang, Chunxia Du, et al.. (2024). Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial. Gastric Cancer. 27(3). 571–579. 10 indexed citations

Zhang, Jing, et al.. (2024). Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer. Investigational New Drugs. 42(4). 454–461. 1 indexed citations

Wu, Guifu, et al.. (2024). Case report: Immunotherapy in rare high TMB pancreatic acinar carcinoma. Frontiers in Oncology. 14. 1357233–1357233.

Yang, Lin, et al.. (2024). Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).. Journal of Clinical Oncology. 42(16_suppl). 4037–4037.

Li, Huixian, Hui Zheng, Wei Tang, et al.. (2023). Postoperative recurarization after sugammadex administration in two patients who received neoadjuvant chemotherapy: case reports and literature review. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 70(9). 1529–1538. 2 indexed citations

Fang, Yuting, et al.. (2023). Recent advances in targeted therapy for pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology. 15(4). 571–595. 30 indexed citations

Zhang, Wen, Xinyu Bi, Yongkun Sun, et al.. (2022). Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients. Clinical Cancer Research. 28(16). 3499–3508. 42 indexed citations

10.

Qian, Haili, et al.. (2022). Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated. Cancer Cell International. 22(1). 341–341. 6 indexed citations

11.

Zhou, Aiping, et al.. (2022). Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study. BMC Cancer. 22(1). 253–253. 4 indexed citations

12.

Sun, Yongkun, Aiping Zhou, Wen Zhang, et al.. (2021). Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatology International. 15(3). 621–629. 41 indexed citations

13.

Chi, Yihebali, Jing Zhang, Yang Yang, et al.. (2021). Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial. International Journal of Clinical Oncology. 26(9). 1611–1618. 3 indexed citations

14.

Chen, Yangchao, et al.. (2019). Loss of Cirbp expression is correlated with the malignant progression and poor prognosis in nasopharyngeal carcinoma. SHILAP Revista de lepidopterología. 1 indexed citations

15.

Jiang, Shiyu, Sheng Yang, Jianliang Yang, et al.. (2019). Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. BMJ Open. 9(5). e028589–e028589. 1 indexed citations

16.

Mohanlal, Ramon, Yongkun Sun, Goetz Kloecker, et al.. (2019). P2.01-23 DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone in Stage IIIb/IV NSCLC. Journal of Thoracic Oncology. 14(10). S647–S648. 6 indexed citations

17.

Chi, Yihebali, Zhiwei Fang, Xiaonan Hong, et al.. (2018). Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 24(21). 5233–5238. 245 indexed citations

18.

Zhang, Wen, Chunxia Du, Yongkun Sun, et al.. (2018). Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemotherapy and Pharmacology. 82(4). 655–660. 21 indexed citations

19.

Sun, Yongkun, Shangying Hu, Yong Jiang, et al.. (2017). Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterology. 17(1). 41–41. 46 indexed citations

20.

Du, Feng, Susheng Shi, Yongkun Sun, Jinwan Wang, & Yihebali Chi. (2015). Clinicopathological Characteristics and Prognosis of Colorectal Cancer in Chinese Adolescent Patients. Chinese Medical Journal. 128(23). 3149–3152. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact